|
1
|
Rauf N, Tahir SS, Dilawar S, Ahmad I and
Parvez S: Serum selenium concentration in liver cirrhotic patients
suffering from hepatitis B and C in Pakistan. Biol Trace Elem Res.
145:144–150. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gabrielson A, Tesfaye AA, Marshall JL,
Pishvaian MJ, Smaglo B, Jha R, Dorsch-Vogel K, Wang H and He AR:
Phase II study of temozolomide and veliparib combination therapy
for sorafenib-refractory advanced hepatocellular carcinoma. Cancer
Chemother Pharmacol. 76:1073–1079. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Senggunprai L, Kukongviriyapan V, Prawan A
and Kukongviriyapan U: Quercetin and EGCG exhibit chemopreventive
effects in cholangiocarcinoma cells via suppression of JAK/STAT
signaling pathway. Phytother Res. 28:841–848. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koike K, Takaki A, Tatsukawa M, Suzuki M,
Shiraha H, Iwasaki Y, Sakaguchi K and Shiratori Y: Combination of
5-FU and IFNalpha enhances IFN signaling pathway and caspase-8
activity, resulting in marked apoptosis in hepatoma cell lines. Int
J Oncol. 29:1253–1261. 2006.PubMed/NCBI
|
|
5
|
Wu XQ, Dai Y, Yang Y, Huang C, Meng XM, Wu
BM and Li J: Emerging role of miRNAs in regulating macrophage
activation and polarization in immune response and inflammation.
Immunology. 148:237–248. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Piontek K and Selaru FM: MicroRNAs in the
biology and diagnosis of cholangiocarcinoma. Semin Liver Dis.
35:55–62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ge YS, Xu GL, Zhang CH, Jia WD, Li JS, Ma
JL and Yu JH: Efficacy and feasibility of radiofrequency ablation
for hepatocellular carcinoma patients. Hepatogastroenterology.
59:2540–2542. 2012.PubMed/NCBI
|
|
9
|
Safran H, Charpentier KP, Kaubisch A,
Mantripragada K, Dubel G, Perez K, Faricy-Anderson K, Miner T, Eng
Y, Victor J, et al: Lenalidomide for second-line treatment of
advanced hepatocellular cancer: A brown university oncology group
phase II study. Am J Clin Oncol. 38:1–4. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu AX, Holalkere NS, Muzikansky A, Horgan
K and Sahani DV: Early antiangiogenic activity of bevacizumab
evaluated by computed tomography perfusion scan in patients with
advanced hepatocellular carcinoma. Oncologist. 13:120–125. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saxena NK, Sharma D, Ding X, Lin S, Marra
F, Merlin D and Anania FA: Concomitant activation of the JAK/STAT,
PI3K/AKT, and ERK signaling is involved in leptin-mediated
promotion of invasion and migration of hepatocellular carcinoma
cells. Cancer Res. 67:2497–2507. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lejeune D, Dumoutier L, Constantinescu S,
Kruijer W, Schuringa JJ and Renauld JC: Interleukin-22 (IL-22)
activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a
rat hepatoma cell line. Pathways that are shared with and distinct
from IL-10. J Biol Chem. 277:33676–33682. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schaper F, Siewert E, Gomez-Lechon MJ,
Gatsios P, Sachs M, Birchmeier W, Heinrich PC and Castell J:
Hepatocyte growth factor/scatter factor (HGF/SF) signals via the
STAT3/APRF transcription factor in human hepatoma cells and
hepatocytes. FEBS Lett. 405:99–103. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Inamura K, Matsuzaki Y, Uematsu N, Honda
A, Tanaka N and Uchida K: Rapid inhibition of MAPK signaling and
anti-proliferation effect via JAK/STAT signaling by
interferon-alpha in hepatocellular carcinoma cell lines. Biochim
Biophys Acta. 1745:401–410. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kang FB, Wang L, Jia HC, Li D, Li HJ,
Zhang YG and Sun DX: B7-H3 promotes aggression and invasion of
hepatocellular carcinoma by targeting epithelial-to-mesenchymal
transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int.
15:452015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hunecke D, Spanel R, Langer F, Nam SW and
Borlak J: MYC-regulated genes involved in liver cell dysplasia
identified in a transgenic model of liver cancer. J Pathol.
228:520–533. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu H, Radisky DC, Yang D, Xu R, Radisky
ES, Bissell MJ and Bishop JM: MYC suppresses cancer metastasis by
direct transcriptional silencing of alphav and beta3 integrin
subunits. Nat Cell Biol. 14:567–574. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li L, Jin R, Zhang X, Lv F, Liu L, Liu D,
Liu K, Li N and Chen D: Oncogenic activation of glypican-3 by c-Myc
in human hepatocellular carcinoma. Hepatology. 56:1380–1390. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leskov I, Pallasch CP, Drake A, Iliopoulou
BP, Souza A, Shen CH, Schweighofer CD, Abruzzo L, Frenzel LP,
Wendtner CM, et al: Rapid generation of human B-cell lymphomas via
combined expression of Myc and Bcl2 and their use as a preclinical
model for biological therapies. Oncogene. 32:1066–1072. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang XW and Xu B: Differential regulation
of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase
activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2
cells. Anticancer Drugs. 11:747–756. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Z, Medrzycki M, Bunting ST and
Bunting KD: Stat5-deficient hematopoiesis is permissive for
Myc-induced B-cell leukemogenesis. Oncotarget. 6:28961–28972.
2015.PubMed/NCBI
|
